In a recent video, Dr. Marlene Freeman delivers an expert commentary on postpartum OCD, highlighting research showing intrusive thoughts are common, distressing, and not linked to infant harm.
New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Topiramate exposure in early pregnancy is linked to higher rates of major malformations and more specifically to increased risk of oral clefts, with risk rising at higher doses.
Emerging data suggest women with endometriosis face a higher risk of postpartum depression and anxiety, underscoring the need for proactive screening and individualized care.
AI and machine learning models, using tools like the EPDS and data from the electronic health record, may help clinicians detect and even prevent postpartum depression.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Whether through donations, knowledge, resources, infrastructure, advocacy, education, training, mentoring, or time, contributing to women's advancement helps create a more supportive and interconnected world.
Virtual group prenatal care was linked to reduced stress and higher perceived quality of care, offering a promising model to support maternal well-being and access to care.
Early identification and treatment of maternal sleep problems during pregnancy may lower the risk for postpartum depression and improve both maternal and infant sleep outcomes.
